Rachel is a seasoned healthcare executive and investment banker with more than 30 years of experience, known for her strategy and active portfolio management expertise and ability to build strong, high-impact teams. As Chief Strategy & Corporate Development Officer for Solventum, she is focused on setting the company’s strategic direction and portfolio transformation roadmap, and executing inorganic actions to drive long-term growth.
Before joining Solventum in March 2025, she served as the Chief Administrative Officer and Chief Strategy Officer for Zimmer Biomet, with responsibility for strategy, business development, integration, communications and corporate marketing. During her tenure, Rachel was responsible for strategy development and deployment, and executed numerous acquisitions and strategic partnerships, driving revenue growth while advancing business strategies. She also led the spin-off of Zimmer Biomet’s spine and dental businesses to create ZimVie, an independent public company.
Prior to joining Zimmer Biomet, Rachel held successive leadership roles across numerous functions at St. Jude Medical. She led the successful integration of Thoratec, the company’s largest acquisition, as well as the integration of St. Jude Medical during its acquisition by Abbott, still one of the largest acquisitions in med tech history. She joined St. Jude Medical through its acquisition of AGA Medical, where she served as VP, Business Development and Investor Relations.
Rachel started her career in investment banking and ultimately rose to Managing Director with Bank of America’s Healthcare Investment Banking Group.